Compatibility mechanism of Chrysanthemi Indici Flos compound against hepatocellular carcinoma based on balance of DNMTs/TET2

IF 11.2 4区 医学 Q1 CHEMISTRY, MEDICINAL
Chinese Herbal Medicines Pub Date : 2026-07-01 Epub Date: 2026-03-09 DOI:10.1016/j.chmed.2026.03.003
Zehui He, Cancan Guo, Fangping Zhang, Feifan Li, Yu Zhou, Leyi Ma, Xiaohui Wang, Yuefeng Bi
{"title":"Compatibility mechanism of Chrysanthemi Indici Flos compound against hepatocellular carcinoma based on balance of DNMTs/TET2","authors":"Zehui He,&nbsp;Cancan Guo,&nbsp;Fangping Zhang,&nbsp;Feifan Li,&nbsp;Yu Zhou,&nbsp;Leyi Ma,&nbsp;Xiaohui Wang,&nbsp;Yuefeng Bi","doi":"10.1016/j.chmed.2026.03.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>At present, traditional Chinese medicine (TCM) compounds is widely used in tumor therapy. However, due to the current single and simplistic efficacy evaluation indicators that are detached from the guidance of TCM theory, the elucidation of its mechanisms of efficacy is hindered. Therefore, the compatibility mechanism of <em>Chrysanthemi Indici Flos</em> compound (YJHFF) against hepatocellular carcinoma based on DNA methyltransferases/DNA demethylase ten-eleven translocation 2 (DNMTs/TET2) balanced relationship was explored according to the concept of the overall balance of TCM.</div></div><div><h3>Methods</h3><div>This study screened the best compound compatibility ratio in the <em>in vitro</em> experiments, cell viability and DNMTs/TET2 balance were used as evaluation indicators to investigate the effects of single herb and different compatibility of compound on HepG2 and H22 cells. <em>In vivo</em> experiments were conduct on H22 liver orthotopic transplantation model mice. After treatment, the tumor tissues were observed by hematoxylin-eosin (HE), TUNEL and Ki67 immunohistochemical staining, respectively. The oxidative stress and liver function indicators in serum were detected by enzyme-linked immunosorbent assay. In addition, the proportion of tumor-infiltrating lymphocytes was detected by immunofluorescence staining. The mRNA expression levels of <em>DNMTs</em> and <em>TET2</em> in tumor tissues were detected by RT-PCR.</div></div><div><h3>Results</h3><div>The results of <em>in vitro</em> experiments showed that the cell proliferation inhibition rate was highly consistent with the change trend of DNMTs/TET2 balance, accordingly, this study obtained the optimal formula YJHFF. In the <em>in vivo</em> experiments, the tumor growth inhibition rate of YJHFF in 5 g/kg was 62.97%. Extensive necrosis, increased apoptosis and inhibited proliferation activity were observed in tumor tissue. Furthermore, the serum SOD activity was significantly increased, MDA, ALT, AST and AFP levels were significantly decreased, suggesting YJHFF could systematically alleviated oxidative stress and improved liver function. Besides, the infiltration of CD3<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes increased significantly, indicating that the body’s anti-tumor immune response was enhanced. Finally, RT-PCR analysis confirmed that antitumor effects were closely related to the core mechanism of DNMTs/TET2 expression regulation and reconstruction of epigenetic balance.</div></div><div><h3>Conclusion</h3><div>This work confirmed the rationality and feasibility of the DNMTs/TET2 balance relationship as an evaluation indicator for the study of the compatibility mechanism of TCM compounds. The YJHFF screened under the guidance of DNMTs/TET2 balance has liver protection and tumor immune function, showing good anti-hepatocellular carcinoma effect.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 725-736"},"PeriodicalIF":11.2000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Herbal Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1674638426000389","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

At present, traditional Chinese medicine (TCM) compounds is widely used in tumor therapy. However, due to the current single and simplistic efficacy evaluation indicators that are detached from the guidance of TCM theory, the elucidation of its mechanisms of efficacy is hindered. Therefore, the compatibility mechanism of Chrysanthemi Indici Flos compound (YJHFF) against hepatocellular carcinoma based on DNA methyltransferases/DNA demethylase ten-eleven translocation 2 (DNMTs/TET2) balanced relationship was explored according to the concept of the overall balance of TCM.

Methods

This study screened the best compound compatibility ratio in the in vitro experiments, cell viability and DNMTs/TET2 balance were used as evaluation indicators to investigate the effects of single herb and different compatibility of compound on HepG2 and H22 cells. In vivo experiments were conduct on H22 liver orthotopic transplantation model mice. After treatment, the tumor tissues were observed by hematoxylin-eosin (HE), TUNEL and Ki67 immunohistochemical staining, respectively. The oxidative stress and liver function indicators in serum were detected by enzyme-linked immunosorbent assay. In addition, the proportion of tumor-infiltrating lymphocytes was detected by immunofluorescence staining. The mRNA expression levels of DNMTs and TET2 in tumor tissues were detected by RT-PCR.

Results

The results of in vitro experiments showed that the cell proliferation inhibition rate was highly consistent with the change trend of DNMTs/TET2 balance, accordingly, this study obtained the optimal formula YJHFF. In the in vivo experiments, the tumor growth inhibition rate of YJHFF in 5 g/kg was 62.97%. Extensive necrosis, increased apoptosis and inhibited proliferation activity were observed in tumor tissue. Furthermore, the serum SOD activity was significantly increased, MDA, ALT, AST and AFP levels were significantly decreased, suggesting YJHFF could systematically alleviated oxidative stress and improved liver function. Besides, the infiltration of CD3+, CD4+ and CD8+ T lymphocytes increased significantly, indicating that the body’s anti-tumor immune response was enhanced. Finally, RT-PCR analysis confirmed that antitumor effects were closely related to the core mechanism of DNMTs/TET2 expression regulation and reconstruction of epigenetic balance.

Conclusion

This work confirmed the rationality and feasibility of the DNMTs/TET2 balance relationship as an evaluation indicator for the study of the compatibility mechanism of TCM compounds. The YJHFF screened under the guidance of DNMTs/TET2 balance has liver protection and tumor immune function, showing good anti-hepatocellular carcinoma effect.
基于dnmt /TET2平衡的菊花化合物抗肝癌的相容性机制
目的:目前,中药复方在肿瘤治疗中应用广泛。但目前的疗效评价指标单一、过于简单化,脱离了中医理论的指导,阻碍了对其疗效机制的阐明。因此,根据中医整体平衡的概念,探讨菊花化合物(YJHFF)基于DNA甲基转移酶/DNA去甲基化酶10 - 11易位2 (dnmt /TET2)平衡关系的抗肝癌配型机制。方法:筛选体外实验中最佳配伍比例,以细胞活力和DNMTs/TET2平衡为评价指标,考察单一中药及不同配伍的复方对HepG2和H22细胞的影响。采用H22肝原位移植模型小鼠进行体内实验。治疗后分别采用苏木精-伊红(HE)、TUNEL、Ki67免疫组化染色观察肿瘤组织。采用酶联免疫吸附法检测血清氧化应激和肝功能指标。免疫荧光染色检测肿瘤浸润淋巴细胞比例。采用RT-PCR检测肿瘤组织中dnmt和TET2 mRNA表达水平。结果:体外实验结果显示,细胞增殖抑制率与dnmt /TET2平衡的变化趋势高度一致,据此,本研究获得了最佳配方YJHFF。在体内实验中,5 g/kg的YJHFF对肿瘤生长的抑制率为62.97%。肿瘤组织广泛坏死,细胞凋亡增加,增殖活性受到抑制。血清SOD活性显著升高,MDA、ALT、AST、AFP水平显著降低,提示YJHFF能系统缓解氧化应激,改善肝功能。此外,CD3+、CD4+、CD8+ T淋巴细胞浸润明显增加,表明机体抗肿瘤免疫反应增强。最后,通过RT-PCR分析证实其抗肿瘤作用与dnmt /TET2表达调控和表观遗传平衡重建的核心机制密切相关。结论:本工作证实了dnmt /TET2平衡关系作为中药复方配伍机制研究的评价指标的合理性和可行性。在DNMTs/TET2平衡指导下筛选的YJHFF具有肝脏保护和肿瘤免疫功能,具有良好的抗肝细胞癌效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chinese Herbal Medicines
Chinese Herbal Medicines CHEMISTRY, MEDICINAL-
CiteScore
4.40
自引率
5.30%
发文量
629
审稿时长
10 weeks
期刊介绍: Chinese Herbal Medicines is intended to disseminate the latest developments and research progress in traditional and herbal medical sciences to researchers, practitioners, academics and administrators worldwide in the field of traditional and herbal medicines. The journal's international coverage ensures that research and progress from all regions of the world are widely included. CHM is a core journal of Chinese science and technology. The journal entered into the ESCI database in 2017, and then was included in PMC, Scopus and other important international search systems. In 2019, CHM was successfully selected for the “China Science and Technology Journal Excellence Action Plan” project, which has markedly improved its international influence and industry popularity. CHM obtained the first impact factor of 3.8 in Journal Citation Reports (JCR) in 2023.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书